Sign in
CompletedPhase 4

Solriamfetol and CBT-I in Patients With Insomnia Disorder

Key facts

Who runs it
University of Pennsylvania
Where
Philadelphia, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 4
People taking part
115 people enrolled
Started
31 Jul 2023
Ended
30 Apr 2026
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Solriamfetol 75 MG
  • Cognitive Behavioral Therapy for Insomnia (CBT-I)
  • Monitoring
  • Placebo
Record updated
12 May 2026

Who can take part

Age
25 years to 60 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Participants will meet the diagnostic criteria for Insomnia Disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSM-5); In addition, the complaint of disturbed sleep will meet the following criteria:
  • ≥ 30 minutes to fall asleep (SL) and/or ≥ 2 awakenings per night of ≥ 15 minutes duration and/or wake after sleep onset (WASO) time of ≥ 30 minutes where total sleep time (TST) did not exceed 6 hours (unless sleep efficiency [SE] is ≤ 80%)
  • The problem is present for > 3 nights per week
  • The problem duration exceeds ≥ 6 months
  • The complaint of impaired daytime function must include, although not limited to, the report of daytime fatigue, sleepiness, or both
  • Preferred regular sleep phase between 10:00 PM and 8:00 AM
  • Must garner physician's assent from their primary care clinician

Who cannot take part

  • Use of medication expressly for the purpose of falling or staying asleep (e.g., trazodone/ desyrel, melatonin, Tylenol PM, Nyquil, Benadryl)
  • Use of CNS active medications that are for treatment of insomnia or are thought to have caused insomnia as a side effect
  • Major Coronary Artery Disease and/or uncontrolled (with meds) Hypertension
  • Unstable medical or psychiatric illness
  • Symptoms suggestive of sleep disorders other than insomnia
  • Polysomnographic data indicating sleep disorders other than insomnia
  • Night shift work
  • Compromised renal function
  • Planning to become pregnant, pregnant, and/or breastfeeding
  • Evidence of active illicit substance use, abuse, or dependence
  • Inadequate language comprehension
  • Current or past experience with CBT-I
  • No access to the computers, I-Pads, or the internet

Where in United States

  • University Of Pennsylvania, Behavioral Sleep Medicine ProgramPhiladelphia, United States

About the trial

What the trial wants to find out

Medication is FDA approved. The objective of this project is to test the efficacy of solriamfetol for treating insomnia (alone and in combination with Cognitive Behavioral Therapy for Insomnia [CBT-I]). Ultimately, this study will test whether wake extension (regardless of how it is achieved) will consolidate sleep and improve sleep continuity.

The 4 groups in the trial

  • Solriamfetol+ CBT-ITreatment being tested

    Treatment: Solriamfetol 75 MG and Cognitive Behavioral Therapy for Insomnia (CBT-I)

  • Solriamfetol OnlyTreatment being tested

    Treatment: Solriamfetol 75 MG and Monitoring

  • Placebo + CBT-IExisting treatment, for comparison

    Treatment: Cognitive Behavioral Therapy for Insomnia (CBT-I) and Placebo

  • Placebo OnlyPlacebo, for comparison

    Treatment: Monitoring and Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Effects of Solriamfetol and CBT-I (Alone and in Combination) on Sleep Continuity, Sleepiness, Fatigue, and Performance in Patients With Insomnia Disorder
Record updated
12 May 2026